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 Chapter 8 
 TLR4-Dependent Tumor-Initiating Stem 
Cell- Like Cells (TICs) in Alcohol-Associated 
Hepatocellular Carcinogenesis 
 Keigo  Machida ,  Douglas  E.  Feldman , and  Hidekazu  Tsukamoto 
 Abstract  Alcohol abuse predisposes individuals to the development of hepatocellu-
lar carcinoma (HCC) and synergistically heightens the HCC risk in patients infected 
with hepatitis C virus (HCV). The mechanisms of this synergism have been elusive 
until our recent demonstration of the obligatory role of ectopically expressed TLR4 in 
liver tumorigenesis in alcohol-fed HCV  Ns5a or  Core transgenic mice. CD133+/
CD49f+ tumor-initiating stem cell-like cells (TICs) isolated from these models are 
tumorigenic in a manner dependent on TLR4 and NANOG. TICs’ tumor-initiating 
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activity and chemoresistance are causally associated with inhibition of TGF-β tumor 
suppressor pathway due to NANOG-mediated expression of IGF2BP3 and YAP1. 
TLR4/NANOG activation causes p53 degradation via phosphorylation of the protec-
tive protein NUMB and its dissociation from p53 by the oncoprotein TBC1D15. 
Nutrient deprivation reduces overexpressed TBC1D15 in TICs via autophagy-medi-
ated degradation, suggesting a possible role of this oncoprotein in linking metabolic 
reprogramming and self-renewal. 
 Keywords  HCC •  Cancer stem cells •  NANOG •  TGF-β •  p53 
8.1  Introduction 
 Hepatocellular carcinoma (HCC) is the most prevalent primary malignancy of the 
liver and the fi fth most common cancer in men. HCC is diagnosed in over half a 
million patients globally every year and is the second leading cause of the cancer- 
related mortality. Cirrhosis is the single and most important risk factor for HCC, 
raising the risk by 40-fold, and about 70 % of HCC patients have underlying cir-
rhosis. With respect to HCC risk by etiology, viral hepatitis (HBV and HCV) is 
most common, followed by alcoholic liver disease (ALD). In particular, chronic 
infection with HCV represents a major global risk factor for HCC [ 1 ] as more than 
170 million people are infected with HCV worldwide [ 1 – 3 ]. HCV produces pro-
teins which are directly implicated in hepatocyte toxicity and transformation. For 
instance, the HCV core protein causes overproduction of reactive oxygen species 
which may cause mitochondrial or nuclear DNA damage [ 2 ,  4 ,  5 ]. The core protein 
also inhibits microsomal triglyceride transfer protein activity and VLDL secretion 
[ 6 ], which contributes the genesis of fatty liver. The core also induces insulin resis-
tance in mice and cell lines, and this effect may be mediated by degradation of 
insulin receptor substrates (IRS) 1 and 2 via upregulation of SOCS3 [ 7 ] in a manner 
dependent on PA28γ 73, or via IRS serine phosphorylation [ 8 ]. These mechanisms 
may also be relevant to another etiological entity which promotes HCC risk: non- 
alcoholic fatty liver disease (NAFLD) [ 9 ] that is a liver phenotype of obesity- 
associated metabolic syndrome. HCV/HBV infection, ALD, and NAFLD share 
common pathophysiological events such as oxidant stress, organelle stress, and 
metabolic dysregulation which may contribute to their oncogenic activities. More 
importantly, an apparent synergism among HCV, alcohol, and obesity exists for the 
risk of HCC. Coexistence of alcohol abuse or obesity increases the HCV risk of 
developing HCC by additional eightfold, culminating to an overall 45–55-fold 
increase in the risk as compared to normal subjects [ 10 ,  11 ] (Fig.  8.1 ). As alcohol 
and obesity continue to dominate as leading life-style factors for disease burdens 
around the world [ 12 ], heightened HCC incidence, caused by synergistic interac-
tions of these factors with hepatitis viruses, represents the most predictable and 
devastating global health issue.
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 The most challenging aspect of HCC treatment is its refractoriness to chemo-
therapy. Among many potential mechanisms which underlie chemoresistance, the 
role of tumor-initiating stem cell-like cells (TICs) or the so-called cancer stem cells 
(CSCs) has received a spotlight. Stem cells have three major characteristics, self- 
renewal, asymmetric division (clonality), and plasticity. Forty percent of HCC are 
assumed to have clonality and to originate from progenitor/stem cells [ 13 – 16 ]. 
CD133+/CD49f+ cells in liver tumors correlate with tumorigenesity and the expres-
sion of “stemness” genes, such as Wnt/β-catenin, Notch, Hedgehog/SMO, and 
Oct3/4 [ 17 – 19 ]. Indeed, CD133+/CD49f+ HCC CSCs are chemoresistant [ 20 ] and 
survive during an initial therapy. Although an encouraging therapeutic response 
may be seen, survived CSCs eventually establish a clonal expansion and tumor 
recurrence. This chemoresistance may be caused by the plasticity of CSCs with 
dysregulated signaling and gene expression. Several oncogenic signaling pathways 
are activated in HCC or CSCs, including PI3K/AKT [ 21 ], signal transducer and 
activator of transcription 3 (STAT3) [ 22 ,  23 ], and hedgehog [ 24 ,  25 ] while defective 
tumor suppressor transforming growth factor-beta (TGF-β) pathway is also impli-
cated [ 26 ,  27 ]. Another pivotal mechanism is asymmetric division of CSCs produc-
ing dormant daughter cells which are less sensitive to chemotherapeutic drugs. 
8.2  Ectopic TLR4 Activation Underlies HCV-Alcohol 
Synergism 
 In our efforts to establish mouse models of HCV-alcohol synergism for HCC, we 
fed fi rst alcohol to HCV  Ns5a transgenic mice by using the mouse intragastric feed-
ing (iG) model. This approach is prompted by the observation that TLR4 expression 
is induced in the liver by hepatocyte-specifi c NS5A expression [ 28 ]. As endotoxin- 
TLR4 pathway is established in the pathogenesis of ALD [ 29 ,  30 ], a synergism 
between alcohol-mediated endotoxemia and NS5A-induced TLR4 overexpression 
was predicted. Indeed, alcohol feeding to the  Ns5a mice results in aggravated liver 
damage with severe hepatitis induced in some mice [ 31 ]. This pathology is depen-
dent on TLR4 as it is abrogated in alcohol-fed  Ns5a:Tlr4−/− mice. This synergism 
is also due to endotoxin as it is attenuated by the concomitant treatment of the mice 
with polymyxin B and neomycin and is conversely potentiated by intragastric 
administration of LPS. To extend this observation to an extended period of 12 
 Fig. 8.1  Synergistically increased risk for HCV-mediated HCC by alcohol abuse or/and obesity. 
Comorbidity such as alcohol abuse and obesity synergistically heightens the risk of developing 
HCC by 6- to 8-fold in HCV-infected patients. As such HCV-infected, alcoholic or obese patients 
have 40–60 times higher HCC risk compared to healthy subjects 
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months, a modifi ed ethanol-containing liquid diet was fed to  Ns5a and  Ns5a:Tlr4−/− 
mice. Although no liver tumor is observed in none of wild type (WT) or  Ns5a:Tlr4−/− 
mice fed alcohol, 23 % of alcohol-fed  Ns5a Tg mice developed liver tumors [ 31 ]. 
This TLR4-dependent tumorigenic phenotype was subsequently reproduced in 
alcohol-fed HCV  Core Tg mice [ 32 ]. 
8.3  Identifi cation of TLR4/NANOG-Dependent TICs 
 Immunostaining of liver tumor sections from alcohol-fed  Ns5a mice revealed cells 
double-positive for NANOG and CD133 or CD49f [ 31 ]. This prompted a FACS 
analysis of cells dissociated from liver tumors of these mice which detected a small 
yet signifi cantly increased percentage of CD133+/CD49f+ cells as compared to WT 
mice (1.11 % vs. 0.05 %). Gene profi ling analysis of sorted CD133+/CD49+ cells 
shows consistently upregulated stemness genes such as  Nanog, Oct4, Sox2 as 
 compared to CD133−/CD49+ or CD133−/CD49f− cells. 
 This heightened expression of stemness genes and cell proliferation are largely 
reduced by TLR4 silencing with lentiviral short-hairpin RNA (shRNA) compared to 
control CD133−/CD49f+ cells [ 32 ]. The CD133+/CD49f+ cells form colonies in 
soft agar and spheroids in ultra-low-adhesion plates, demonstrating they have 
anchorage-independent growth and self-renewal ability [ 32 ]. Subcutaneous trans-
plantation of CD133+/CD49f+ cells , but not CD133−/CD49f+ cells into immuno-
compromised (NOG) mice, following infection with a red-fl uorescence (dsRed) 
lentiviral vector, results in tumor development; and this tumor growth, assessed by 
dsRed imaging, is inhibited by  Tlr4 or  Nanog silencing by lentiviral shRNA trans-
duced prior to transplantation [ 32 ] (Fig.  8.2 ), indicating that CD133+/CD49f+ cells 
are TLR4/NANOG-dependent TICs and that  Tlr4 is a putative proto-oncogene 
involved in the genesis/maintenance of TICs and liver tumor in HCV Tg models. 
Furthermore, these NOG mice derived tumor have tumor-initiation capacity since 
injection of serial transplantation of these tumors into another NOG mice generates 
tumors in NOG mice. Then one will raise a question where these TICs are generated. 
These TICs may have been generated from hepatoblasts in several etiologies since 
hepatoblastic HCC subtype with poor prognosis has a gene expression profi le with 
markers of hepatic oval cells, suggesting that this subtype of HCC arises from LPCs 
[ 33 – 36 ]. Indeed, these HCC often recurs after chemotherapy presumably due to the 
presence of chemo-resistant TICs [ 37 ]. These aspects need further investigation.
8.4  TLR4 as a Putative Proto-oncogene 
 The obligatory roles of endotoxin and TLR4 in HCC promotion are shown in vari-
ous etiological settings including initiation in alcohol-HCV model and promotion 
[ 32 ] in the DEN/CCl 4 model [ 38 ]. Activated TLR4 pathway is responsible for 
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promotion of HCCs from different animal models [ 38 ], which offer new therapeutic 
targets for HCC. As PAMP (pathogen-associated molecular pattern), including 
TLR4, mediates infl ammatory responses to endotoxin and other ligands, infl amma-
tion is strongly associated with cancer in other cancers, including lung [ 39 ], colon 
[ 40 ], and skin carcinomas [ 41 ]. While TLR expression is very heightened in macro-
phages and lymphocytes, normal hepatocytes have less or nonfunctional TLR4, but 
ectopically expressed-TLR4 in epithelial cells is involved in oncogenesis as studies 
in other cancer models implicate liver has also similar oncogenic pathways since 
gut-derived endotoxin directly damages liver due to proximal anatomy of gut and 
liver through portal veins [ 31 ,  38 ,  42 ]. As we mentioned above, we have shown that 
long-term (12 months) feeding of alcohol diet induces liver tumors in HCV  Ns5a Tg 
mice [ 43 – 46 ] and these incidences are reduced if the mice were crossbred with 
defective  Tlr4 mice [ 32 ]. Plasma LPS levels are elevated equally in both TLR4 suf-
fi cient and defi cient mice fed these diets, indicating that ligand level is not changed 
even by disruption of its receptor  Tlr4 [ 31 ,  32 ]. Indeed, tumor tissues from  Tlr4+/+ 
models display accentuated expression of TLR4 and its activation as assessed by its 
 Fig. 8.2  TICs’ tumorigenic activity is dependent on TLR4 and NANOG. CD133+/CD49f+ TICs 
isolated from liver tumors of alcohol-fed  Ns5a Tg mice or alcoholic HCV patients were trans-
planted subcutaneously into NOG mice following lentiviral transduction of EGFP to allow a whole 
animal imaging for assessment of tumor growth for a period of 80 days. To test the dependence on 
TLR4 and NANOG, they were respectively knocked down by lentiviral expression of specifi c or 
control shRNA prior to transplantation. Tumor volume was calculated by three dimensional assess-
ment of the tumor image, and fi nal tumor weights were also compared at the end of the experiment. 
Note TLR4 ( a ) or NANOG ( b ) knockdown signifi cantly attenuates tumor growth derived from 
mouse and patient TICs. Immunoblotting of cell lysates collected 10 days after the transplantation 
confi rms expression of NANOG in the TICs and knockdown of this protein with specifi c shRNA. 
* p < 0.05 (Reproduced from the published fi gure of the reference [ 32 ] with permission) 
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downstream marker TRAF6-TAK1 complex formation [ 32 ]. Furthermore, activa-
tion of human TLR4 oncogenic pathway, especially NANOG overexpression, is 
also noted in HCC sections of alcoholic HCV as well as non-steatohepatitis (NASH) 
patients [ 32 ], supporting this activation of TLR4-NANOG axis is clinically relevant 
for the development of both human and mouse HCCs [ 31 ]. TICs are resistant to 
chemotherapy and are associated with metastatic HCC, which is commonly 
observed in HCV-infected patients with alcohol abuse. Sensitization of TICs to che-
motherapy and identifying therapeutic molecular targets could be a considerable 
savings in morbidity, mortality, and cost. However, in HCCs, there are many signal-
ing involved in genesis of HCCs. In the next section, one of the typical crosstalk 
between TLR4 and TGF-β pathways will be discussed. 
8.5  TLR4 and TGF-β Mutual Antagonism 
in Liver Tumorigenesis 
 Our study identifi es TLR4 signaling as a central mediator in synergistic liver tumor 
formation by HCV and alcohol via the genesis of TLR4/NANOG-dependent TICs. 
On the other hand, defi cient TGF-β pathway caused by inactivation of at least one 
of the TGF-β signaling components is a well-known risk factor for HCC in man [ 26 , 
 47 ] and a causal oncogenic mechanism in animal models [ 15 ,  48 ]. Thus, we won-
dered about the relationship between the two pathways. To investigate this question, 
we have used two complementary approaches. First, we looked for TIC-specifi c 
genes which may be involved in regulating TGF-β pathway by screening lentiviral 
cDNA library established from TIC vs. CD133−/CD49f+ control cells for transfor-
mation of the p53 defi cient hepatoblast cell line PL4 [ 32 ]. This has identifi ed  Yap1 
and  Igf2bp3 as two TIC-associated genes which are under direct transcriptional 
control of NANOG and contribute to TICs’ tumor-initiating activities both in vitro 
and in vivo [ 32 ]. Further, these two gene products are shown to inhibit the TGF-β 
tumor suppressor pathway at the two distinct levels but in an interactive manner. 
YAP1 associates with SMAD3 and SMAD7 to block nuclear translocation of 
p-Smad3. IGF2BP3, an mRNA binding protein, promotes IGF-II translation by 
binding to the 5′ UTR of  Igf-II mRNA [ 49 ]. IGF-II activates AKT and subsequently 
mTOR, which suppresses SMAD3 activation [ 50 ]. Indeed, mTOR activation by 
IGF2BP3 inhibits phosphor-activation of SMAD3 as such Rapamycin increases 
p-SMAD3 in TICs or even abrogates suppressed p-SMAD3 level caused by a con-
stitutively active AKT. This IGF2BP3-AKT-mTOR pathway also interfaces with 
the YAP1-SMAD3/SMAD7 pathway described above. Activated AKT phosphory-
lates Ser-127 of YAP1, and p-Ser127-YAP1 interacts most actively with p-SMAD3 
for cytosolic SMAD3 retention. Thus AKT activated by IGF2BP3 facilitates dual 
actions of mTOR-mediated suppression of SMAD3 phosphor-activation and 
p-YAP1-mediated p-SMAD3 retention, resulting in effective blockade of TGF-β 
pathway. As expected, silencing of  Igf2bp3 and  Yap1 in TICs restores TGF-β path-
way with increased nuclear p-SMAD3, reduces TICs’ tumorigenic activity, and 
enhances the chemosensitivity of TICs in vivo [ 32 ]. 
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 We have also used a reverse approach to test the reciprocal TLR4-TGF-β antago-
nism by assessing TLR4 expression and activation in  Spnb2 +/– mice. In fact, it is 
well known in innate immunity that the lack of a functional TβRII [ 51 ,  52 ] or Smad3 
[ 53 ] results in extensive infl ammation due to increased TLR4 expression and LPS 
hyper-responsiveness [ 54 ]. We believe this reciprocal regulation of augmented 
TLR4 response due to defi cient TGF-β signaling also plays a critical role in genera-
tion and oncogenic activity of Nanog+ CSCs. SPNB2 is the chaperone protein 
which recruits p-SMAD3/SMAD4 into the nucleus, and SPNB2 haploinsuffi ciency 
in  Spnb2 +/– mice reduces TGF-β signaling and causes spontaneous development of 
HCC [ 15 ]. TLR4 expression is induced in the liver of this genetic mouse model as 
compared with WT mice. Feeding  Spnb2+/– mice with alcohol for 12 months 
results in conspicuous TLR4 activation as assessed by TAK1/TRAF6 interaction 
and doubles the liver tumor incidence as compared to  Spnb2+/– mice fed with a 
control diet [ 32 ]. More importantly, this increment of the tumor incidence is com-
pletely abrogated in alcohol-fed  Spnb2+/-Tlr4−/− compound mice, demonstrating 
reciprocally upregulated TLR4 in  Spnb2+/– mice with reduced TGF-β signaling, is 
also responsible for alcohol-associated liver tumorigenesis in the model. We readily 
extend this concept to clinically more relevant cells, the Huh7 human HCC cell line. 
Knockdown of SPNB2 in these cells increases TLR4 expression and tumorigenic 
activity in NOG mice [ 32 ]. 
8.6  Anabolic Metabolism and TIC Self-Renewal 
 A critical event leading to deregulated TIC proliferation is inactivation of the p53 
tumor suppressor [ 55 ,  56 ], which acts as a key barrier against pluripotency and stem 
cell proliferation. This function of p53 is carried out through direct repression of 
stemness-associated transcription factor (TF) network components [ 57 ]. Mutation 
or loss of p53 is found recurrently in diverse malignancies including HCC [ 58 ] and 
is associated with poor prognosis [ 59 ,  60 ]. Strikingly, genetic inactivation of p53 
also leads to loss of cell polarity and aberrant execution of self-renewal [ 61 – 63 ]. 
The cell polarity determinant and tumor suppressor NUMB stably interacts directly 
with p53, protecting it from ubiquitin-mediated proteolysis catalyzed by the MDM2 
E3 ubiquitin ligase [ 64 ]. In polarized epithelial cells and in untransformed progeni-
tor cells, NUMB is distributed asymmetrically and segregates into the daughter cell 
that proceeds to differentiate. Cells defi cient in p53 fail to correctly localize NUMB 
and lose this intrinsic polarity [ 65 ,  66 ], however little is understood about the com-
position and regulation of the Numb-p53 complex. 
 We examined biochemically the composition of the Numb-p53 complex in 
CD133+/CD49f+ TICs isolated from liver tumors of alcohol-fed HCV  Ns5aTg 
mice, Fractionation of TIC lysates using sucrose density gradient centrifugation 
revealed that NUMB and p53 are the constituents of a high molecular mass 
(>700 kDa) complex, which is disintegrated upon NANOG-mediated activation 
of aPKCζ, a NUMB kinase [ 67 ]. Using affi nity purifi cation and tandem mass 
 spectrometry, we identifi ed the ATG8/LC3-binding protein TBC1D15 as a novel 
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component of this high molecular mass complex. Enforced expression of TBC1D15 
reduces steady state levels of p53 and this effect is blocked by a Nutlin-3 treatment, 
suggesting that TBC1D15 triggers the MDM2-dependent degradation of p53. 
 TBC1D15 is comprised of two distinct structural domains: a C-terminal GTPase 
activating protein (GAP) domain that inactivates the Rab7 GTPase, which mediates 
endosome/autophagosome-fusion to lysosomes [ 68 ,  69 ] and a functionally unchar-
acterized N-terminal domain. We expressed Flag-tagged variants of each domain 
individually with myc-tagged p53 (myc-p53), and found that the N-terminal domain 
(Flag-TBC1D15-N) recapitulated inhibition of myc-p53. Destabilization of myc- 
p53 corresponded closely with the extent of its displacement from NUMB. Sequence 
analysis of the N-terminal domain revealed a 50 amino acid region containing sig-
nifi cant homology to the  Drosophila protein CANOE, which regulates the localiza-
tion of cell-fate determinants during asymmetric division and interacts genetically 
with  numb [ 70 ,  71 ]. Coexpression of myc-p53 with GFP fusion proteins containing 
either the CANOE homology region (TBC-cno, aa 159–270) or the N-terminal 
region (TBC-N1, aa 2–158) revealed that GFP-TBC-N1 but not GFP-TBC-cno 
associated stably with NUMB, suggesting that a primary sequence or higher order 
structural motif within this region of TBC1D15 directly binds to NUMB and dis-
sociates it from p53 to promote p53 degradation. However, the mutual requirements 
and relative contributions of TBC1D15 and aPKCζ-mediated NUMB phosphoryla-
tion for p53 dissociation and degradation are not yet fully understood and merit 
further investigation. 
 We also found that  Tbc1d15 is transcriptionally repressed by p53, revealing a 
mutually antagonistic regulation between these genes. In agreement with these fi nd-
ings, three human HCC cell lines express TBC1D15 at higher levels than primary 
hepatocytes. In particular, Hep3B cells with p53 defi ciency and Huh7 cells with 
mutant p53 express substantially higher TBC1D15 than HepG2 cells which have 
wild type p53. Thus, p53 levels are inversely correlated with TBC1D15 expression 
in these cells. Similarly, TBC1D15 levels are increased in TICs compared to 
CD133− cells, and TBC1D15 is strongly expressed in tumors arising from TICs 
implanted subcutaneously into mice, as determined by immunohistochemical anal-
ysis of sectioned tumors. 
 Interestingly, the TCTP oncoprotein was also found in association with the 
Numb-p53 complex and shown to stimulate MDM2-mediated proteolysis of p53 
[ 72 ]. These results, along with our recent data on TBC1D15, collectively suggest 
that the Numb-p53 complex may serve as a pivotal control platform that integrates 
multiple inputs to permit the rapid modulation of cellular p53 levels. As there appears 
to be no signifi cant primary sequence homology between TCTP and TBC1D15, 
these proteins may dock with distinct subunits in the NUMB-p53 complex. 
 Cellular levels of TBC1D15 are diminished through starvation-induced autopha-
gic degradation, triggered through acute nutrient deprivation, depletion of ATP or 
chemical inactivation of the mTOR kinase complex. Conversely, TBC1D15 accu-
mulates when autophagic fl ux is blocked. These observations together suggest a 
scenario whereby accumulation of the TBC1D15 oncoprotein drives deregulated 
TIC proliferation and formation of liver tumors due to alcohol-induced suppression 
of autophagy. This proposal resonates with accumulating evidence that suppression 
of autophagy, including through targeted genetic ablation of core autophagic 
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machinery components, promotes the accumulation of oncoproteins leading to 
tumor formation [ 73 – 75 ], underscoring the importance of autophagic degradation 
in the tonic suppression of cancer. These fi ndings suggest that depletion of p53 lev-
els through aPKCζ activation and TBC1D15 upregulation may in turn cause de- 
repression of  Tbc1d15 transcription, further accelerating p53 degradation and 
establishing a self-reinforcing feedback cycle. This cycle represents an attractive 
therapeutic target for inhibition of TICs in HCC, and developing a deeper under-
standing of the aPKCζ-NUMB-TBC1D15 regulatory axis in p53 degradation will 
further defi ne optimal therapeutic targets. 
 More broadly, defi ning the machinery that controls the expansion of TICs will 
have important ramifi cations for cancer treatment. Conventional chemotherapy kills 
a large fraction of tumor cells, resulting in a transient reduction in tumor volume. 
However, it typically fails to eradicate TICs and may actually impose a strong selec-
tive pressure for TIC survival [ 76 ]. As a result, following chemotherapy tumors are 
often enriched with TICs resistant to subsequent treatments. To be effective in the 
long term, cancer therapies will need to include agents that target TIC survival and 
self-renewal. We propose that selective inhibition of the machinery that drives inap-
propriate, self-renewing, symmetrical divisions in TICs will lead to “sterilization” 
of the tumor and to a lasting, benefi cial clinical response. The newly elucidated 
mechanistic framework for TIC proliferation described here represents an innova-
tion that holds signifi cant potential as a prospective therapeutic target. 
8.7  Conclusions and Discussions 
 CD133+ TICs have previously been isolated from liver tumors of PTEN or MAT1A 
defi cient mice [ 51 ,  52 ]. Using the same surface marker, we successfully isolated 
CD133+/CD49f+ TICs which activate a unique TLR4-NANOG pathway as an inte-
gral component for their self-renewal and tumorigenic activities. These TICs are 
also identifi ed in HCC sections of alcoholic HCV patients by immunostaining [ 32 ] 
and isolated from such patients to validate induction of TLR4-dependent stemness 
genes and transformation [ 32 ]. These TICs respond to endotoxin to initiate tumori-
genesis as shown in alcohol-fed HCV Tg mouse models, but TICs isolated from 
alcohol  Core Tg mice and alcoholic HCV patients grow effi ciently in vitro without 
addition of LPS but this growth is reduced by TLR4 knockdown, suggesting LPS- 
independent mechanisms of TLR4 activation in these cells which remain to be elu-
cidated. Possibilities include non-LPS ligands such as HMGB1 released in 
infl ammation activating TLR4 and protein–protein interactions leading to ligand- 
independent activation. Although we began and focused our studies on alcohol- 
HCV synergism, the oncogenic role of TLR4 has been extended to HCC of non-viral 
and non-alcohol etiology such as that in  Spnb+/ − mice and NAFLD patient [ 32 ]. 
A recent study demonstrates the critical role of endotoxin-activated TLR4 in pro-
motion but not initiation of hepatocarcinogenesis induced by diethylnitrosamine 
and carbon tetrachloride [ 38 ]. We believe that the TLR4-dependent mechanisms of 
TIC generation actually contribute to or at least promote the initiation of HCC. 
A conceptual breakthrough of our fi ndings is that the proinfl ammatory  TLR4 is now 
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considered as a putative proto-oncogene in hepatocarcinogenesis that links infl am-
mation to carcinogenesis, the notion which has been entertained for the past 150 
years. Based on this renewed concept, our studies have offered two novel insights 
into the molecular mechanisms of TLR4-mediated TICs’ tumorigenic activity (see 
a schematic diagram shown in Fig.  8.3 ): NANOG-dependent upregulation of 
IGF2BP3 and YAP1 which in turn block the TGF-β tumor suppressor pathway; and 
NANOG-mediated p53 degradation by disengagement from the protective NUMB 
protein via TBC1D15 interaction. These studies are now exploring potential mecha-
nistic connections to metabolic programming known to occur in cancer cells and 
TICs in promoting and maintaining “stem cell fate” via molecular, genetic, and 
epigenetic mechanisms.
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